患者の血液管理の世界市場

患者の血液管理の世界市場は2030年までに236億米ドルに達する見込み

2023年に152億米ドルと推定される患者の血液管理の世界市場は、2023年から2030年にかけてCAGR 6.4%で成長し、2030年には236億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである「機器」は、CAGR6.5%を記録し、分析期間終了時には101億米ドルに達すると予測されます。試薬・キット分野の成長率は、分析期間のCAGRで7.1％と推定されます。

米国市場は推定40億米ドル、中国はCAGR9.8％で成長予測

米国の患者の血液管理市場は2023年に40億米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年の分析期間においてCAGR 9.8%で推移し、2030年には予測市場規模が56億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.3%と5.8%と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

世界の患者の血液管理市場- 主要動向と促進要因のまとめ

現代のヘルスケアにおいて患者の血液管理が不可欠な理由とは？

患者の血液管理（PBM）は、輸血を必要とする可能性のある患者のケアを最適化するための体系的なアプローチを提供し、現代のヘルスケアにおいて極めて重要な要素となっています。PBMは、貧血を管理し、手術中の出血を減らし、患者の赤血球量を最適化することによって輸血の必要性を最小限に抑え、臨床転帰を改善することに焦点を当てています。PBMの重要性は、感染症、免疫反応、輸血関連合併症などの輸血に関連するリスクを軽減することにより、患者の安全性を高める能力にあります。このエビデンスに基づいたアプローチは、血液製剤への依存を減らし、早期回復につながるため、手術や外傷、慢性貧血の患者にとって特に重要です。

不必要な輸血を最小限に抑えることで、PBMはまた、入手可能な量が限られがちな血液供給を節約する上で重要な役割を果たします。このアプローチは、特に血液不足の時や血液製剤へのアクセスが限られている地域のヘルスケアシステムにとって不可欠です。人口の高齢化と外科手術の増加により血液の需要が高まる中、PBMは効率的な血液の使用を促しながら、最も血液を必要とする患者に血液が供給されるようにします。この実践は、資源を節約するだけでなく、輸血に関連するヘルスケアコストを低下させ、PBMを持続可能なヘルスケア管理に不可欠なものにしています。

さらにPBMは、各患者の血液ニーズを管理するために予防的で個別化されたアプローチをとることによって、全体的な転帰の改善を促進します。鉄分の補給、赤血球造血刺激因子製剤、高度な手術手技などの介入を通じて、PBMは手術や治療の前に患者を十分に準備します。この包括的なアプローチにより、合併症の可能性を減らし、入院期間を短縮し、回復時間を延長することができます。ヘルスケアにおいて患者中心のケアがますます重視される中、PBMは現代の医療提供の原則に沿ったオーダーメイドの予防戦略を提供し、患者の満足度と健康アウトカムの両方を向上させる。

技術の進歩は患者の血液管理をどのように強化しているか？

技術の進歩は、血液の使用を最適化し、血液損失を最小限に抑え、患者の転帰を改善する新しいツールや方法を導入することで、患者の血液管理を大きく向上させています。PBMにおける主な技術革新の一つは、手術や治療の前に貧血の早期発見と管理を可能にする高度な診断ツールの開発です。POC（ポイント・オブ・ケア）検査や自動血液分析装置のような技術は、迅速なヘモグロビン評価や鉄欠乏評価を可能にし、ヘルスケア提供者が貧血を早期に診断・治療できるようにします。正確でリアルタイムの診断により、臨床医は事前にヘモグロビン値を最適化するための個別化戦略を実施し、輸血が必要になる可能性を減らすことができます。これらの技術は、PBMの中核要素である予防的貧血管理をサポートし、患者が処置を受ける前に可能な限り最良の状態にあることを保証します。

PBMにおけるもう一つの大きな進歩は、手術中の出血を最小限に抑え輸血の必要性を減らす、細胞サルベージと血液温存手術手技の使用です。術中細胞救済装置は、手術中に患者の血液を回収・処理し、患者に再注入できるようにするもので、これによりドナー血液への依存を減らすことができます。さらに、低侵襲手術や腹腔鏡手術は、切開創が小さいため出血量が少なく、ますます一般的になってきています。これらの手技は、整形外科手術や心臓手術など、出血量の多い手術において特に有益です。細胞サルベージと低侵襲技術を取り入れることで、PBMは外部血液の必要性を減らし、手術結果を改善し、資源効率をサポートします。

赤血球造血刺激因子製剤（ESA）や鉄サプリメントなどの医薬品イノベーションも、赤血球産生を促進し、輸血の必要なく貧血に対処することで、PBMにおいて重要な役割を果たしています。ESAは骨髄を刺激してより多くの赤血球を産生させるので、慢性貧血の患者や化学療法を受けている患者には特に有益です。鉄サプリメントは、経口、静脈注射を問わず、ヘモグロビンの最適化をサポートし、出血を伴う可能性のある処置に備えます。PBMは、輸血の必要性を最小限に抑えながら患者の健康を増進させるという目標に沿い、これらの薬物介入により、貧血管理のための非輸血オプションを提供しています。これらの治療法は、臨床医が各患者のニーズに合わせてPBM戦略を調整することを可能にし、血液管理により効果的で侵襲の少ないアプローチを提供します。

患者の血液管理は患者やヘルスケアプロバイダにとってどのような利点がありますか？

患者の血液管理は、患者とヘルスケアプロバイダーの双方に大きな利益をもたらし、患者の転帰を改善し、ヘルスケアコストを削減し、限られた血液資源の使用を最適化します。患者にとって、PBMは感染症、輸血反応、免疫学的合併症などの輸血に関連するリスクを最小化することにより、安全性を高めます。貧血管理、外科的温存技術、患者自身の血液の使用など、輸血以外の介入を採用することで、PBMは副作用の可能性を減らし、より安全なヘルスケアを促進します。大手術を受ける患者にとって、PBMは、患者の健康を優先し、輸血の必要性を減らし、回復時間の短縮と入院期間の短縮につながる、注意深く管理された血液戦略の保証を提供します。

ヘルスケアプロバイダーにとって、PBMは、供給が限られがちなドナー血液への依存を減らすことで、効率的で持続可能な資源管理をサポートします。献血率が需要の増加に追いつかない中、PBMは外傷や重篤な出血症例など、重要なニーズを持つ患者のために血液資源を確保するのに役立ちます。最適化されたケアと輸血以外の介入によって血液使用量を減らすことで、ヘルスケアプロバイダーはリソースをより効果的に管理することができ、血液不足のリスクを下げ、本当に必要なときに血液製剤を利用できるようにします。PBMはまた、保管、スクリーニング、管理費用など、輸血に関連するコストを削減します。このコスト効率は、血液資源を効果的に管理することで大幅な財政節約につながる大規模病院や医療システムにおいて特に価値があります。

患者の転帰とケアの質の向上は、PBMのその他の特典であり、より患者中心の個別化されたヘルスケアへのアプローチを促進します。貧血の早期発見、血液を節約した外科手術、輸血を行わない選択肢などを通じて、PBMは医療提供者が各患者のニーズに合わせた個別のケアプランを作成することを可能にします。このカスタマイズされたアプローチは、合併症の可能性を減らし、より早い回復をサポートし、患者の満足度と全体的なケアの質を向上させます。患者の血液の健康状態を積極的に管理することで、PBMは入院や再入院を最小限に抑え、より合理的なヘルスケア体験をもたらします。これらの利点が相まって、ヘルスケア提供の臨床面と運営面の両方が改善され、質の高い、費用対効果の高い、患者中心のケアという目標がサポートされます。

患者の血液管理市場の成長を促進しているものは？

患者の血液管理市場の成長の原動力は、輸血関連のリスクに対する意識の高まり、外科手術や慢性疾患の症例の増加、診断・治療技術の進歩、PBMの導入を促進する規制当局の支援政策などです。輸血に関連するリスクや合併症に対する認識が高まるにつれ、ヘルスケアプロバイダーは従来の輸血方法に代わる、より安全で効果的な方法を求めるようになっています。感染症、免疫学的反応、潜在的合併症に対する懸念は、輸血を最小限に抑え、より安全なケアの選択肢を提供するPBMプログラムの必要性を強調しています。このような臨床的観点の変化により、より多くの病院やヘルスケア施設がPBMプロトコルを採用するようになり、包括的な血液管理をサポートする技術や手法に対する需要が高まっています。

手術件数の増加や、がん、腎臓病、心血管疾患などの慢性疾患の有病率の上昇も、PBMソリューションの需要に拍車をかけています。これらの疾患は外科的介入や頻繁な入院を必要とすることが多いため、ヘルスケアプロバイダーは輸血依存を減らしながら患者のケアをサポートする効果的な血液管理戦略を必要としています。PBMプロトコルは、手技前および手技中の患者の血液状態を最適化し、輸血の必要性を減少させるため、出血量の多い手術において特に有用です。手術や入院の件数が増え続けるにつれ、血液を効率的に管理し、患者の転帰を改善するための効果的なPBMソリューションに対する需要も増え続けています。

診断および治療技術の進歩は、より正確で効果的な個別化された血液管理戦略を可能にするため、PBM市場の成長に大きく寄与しています。ポイント・オブ・ケア検査や高度貧血スクリーニングなどの新しい診断ツールは、早期介入と患者の血液レベルの正確な管理を可能にします。細胞救済装置や低侵襲手技を含む外科的技術革新は、手技中の血液損失を減らし、ドナー血液の必要性を最小限にします。赤血球造血刺激因子製剤や静脈内鉄サプリメントなどの医薬品の進歩は、貧血患者に輸血以外の治療選択肢を提供します。こうした技術革新は、PBMプログラムをより利用しやすく効果的なものにし、世界中の病院やヘルスケア施設での採用を後押ししています。

ヘルスケア機関や政府が、患者の安全性の向上と血液資源の最適化におけるPBMの価値を認識しているため、支持的な規制政策やガイドラインもPBM市場の成長を後押ししています。世界保健機関（WHO）のような規制機関や数カ国の保健省は、医療提供者が標準治療プロトコルの一部としてPBMを採用するよう奨励しています。現在、多くのヘルスケアシステムは、品質基準を遵守し、医療費を削減し、血液資源を節約するために、病院にPBM戦略の実施を求めています。さらに、患者擁護団体や医療機関は、医療従事者や一般市民の間でPBMの利点の認知を促進するための教育活動を強化しています。このような規制や擁護の努力はPBMの採用を拡大し、医療提供者がベストプラクティスやコンプライアンス基準に合わせることで市場の大きな成長を促しています。

輸血リスクへの認識、外科手術や慢性疾患の増加、技術の進歩、支持的な規制の枠組みなど、これらの要因が相まって、患者の血液管理市場は力強い成長を遂げています。ヘルスケアシステムが、より安全で費用対効果が高く、資源効率に優れた医療の提供を目指す中、PBMは患者中心の現代的な医療提供の礎となりつつあります。

セグメント

製品（装置、試薬＆キット、ソフトウェア、アクセサリー）;成分（全血＆赤血球、血漿）;エンドユース（血液銀行、病院）

調査対象企業の例（全42社）

• Abbott Laboratories
• Asahi Kasei Medical Co. Ltd.
• B. Braun Melsungen AG
• Biomerieux SA
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche LTD.
• Fresenius Se & Co. KGaA
• Grifols, S.A.
• Haemonetics Corporation
• Immucor, Inc.
• Kaneka Corporation
• Livanova PLC
• Macopharma
• Terumo Corporation

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Patient Blood Management Market to Reach US$23.6 Billion by 2030

The global market for Patient Blood Management estimated at US$15.2 Billion in the year 2023, is expected to reach US$23.6 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Instruments, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$10.1 Billion by the end of the analysis period. Growth in the Reagents & Kits segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.0 Billion While China is Forecast to Grow at 9.8% CAGR

The Patient Blood Management market in the U.S. is estimated at US$4.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.6 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Patient Blood Management Market - Key Trends & Drivers Summarized

Why Is Patient Blood Management Essential in Modern Healthcare?

Patient Blood Management (PBM) has become a crucial component in modern healthcare, providing a systematic approach to optimize the care of patients who might need blood transfusions. PBM focuses on minimizing the need for blood transfusions by managing anemia, reducing blood loss during surgery, and optimizing patients' red blood cell mass, thereby improving clinical outcomes. The importance of PBM lies in its ability to enhance patient safety by reducing the risks associated with transfusions, such as infections, immune reactions, and transfusion-related complications. This evidence-based approach is especially important for patients undergoing surgeries, trauma cases, or those with chronic anemia, as it reduces dependency on blood products and leads to faster recovery.

By minimizing unnecessary transfusions, PBM also plays a significant role in conserving blood supplies, which are often in limited availability. This approach is vital for healthcare systems, particularly in times of blood shortages or in regions with limited access to blood products. With the rising demand for blood due to aging populations and increasing surgical procedures, PBM ensures that blood is available for patients who need it most while encouraging efficient blood use. This practice not only conserves resources but also lowers healthcare costs associated with blood transfusions, making PBM essential for sustainable healthcare management.

Moreover, PBM promotes better overall outcomes by taking a preventive, individualized approach to managing each patient's blood needs. Through interventions like iron supplementation, erythropoiesis-stimulating agents, and advanced surgical techniques, PBM prepares patients adequately before surgery or treatment. This comprehensive approach reduces the likelihood of complications, shortens hospital stays, and enhances recovery times. As healthcare increasingly emphasizes patient-centered care, PBM provides a tailored, preventive strategy that aligns with modern principles of healthcare delivery, improving both patient satisfaction and health outcomes.

How Are Technological Advancements Enhancing Patient Blood Management?

Technological advancements are significantly enhancing Patient Blood Management by introducing new tools and methods that optimize blood use, minimize blood loss, and improve patient outcomes. One key innovation in PBM is the development of advanced diagnostic tools that allow for early detection and management of anemia before surgery or treatment. Technologies like point-of-care (POC) testing and automated blood analyzers enable rapid hemoglobin assessments and iron deficiency evaluations, allowing healthcare providers to diagnose and treat anemia early. With accurate, real-time diagnostics, clinicians can implement personalized strategies to optimize hemoglobin levels in advance, reducing the likelihood of needing transfusions. These technologies support proactive anemia management, a core component of PBM, ensuring that patients are in the best possible condition before undergoing procedures.

Another major advancement in PBM is the use of cell salvage and blood-sparing surgical techniques, which minimize blood loss and reduce transfusion needs during surgery. Intraoperative cell salvage devices collect and process a patient’s blood during surgery, allowing it to be reinfused back into the patient, thus reducing dependency on donor blood. Additionally, minimally invasive and laparoscopic surgical techniques are becoming increasingly common, as they involve smaller incisions, leading to less blood loss. These techniques are particularly beneficial in high-blood-loss surgeries, such as orthopedic and cardiac procedures. By incorporating cell salvage and minimally invasive techniques, PBM reduces the need for external blood, improving surgical outcomes and supporting resource efficiency.

Pharmaceutical innovations, such as erythropoiesis-stimulating agents (ESAs) and iron supplements, are also playing a critical role in PBM by boosting red blood cell production and addressing anemia without the need for transfusions. ESAs stimulate the bone marrow to produce more red blood cells, which is especially beneficial for patients with chronic anemia or those undergoing chemotherapy. Iron supplements, whether oral or intravenous, support hemoglobin optimization, preparing patients for procedures that may involve blood loss. With these pharmaceutical interventions, PBM offers non-transfusion options for managing anemia, aligning with its goal to enhance patient health while minimizing transfusion requirements. These therapies empower clinicians to tailor PBM strategies to each patient’s needs, providing a more effective and less invasive approach to blood management.

What Are the Benefits of Patient Blood Management for Patients and Healthcare Providers?

Patient Blood Management provides significant benefits for both patients and healthcare providers, improving patient outcomes, reducing healthcare costs, and optimizing the use of limited blood supplies. For patients, PBM enhances safety by minimizing the risks associated with blood transfusions, such as infections, transfusion reactions, and immunologic complications. By employing non-transfusion interventions like anemia management, surgical blood-sparing techniques, and the use of patient’s own blood, PBM reduces the potential for adverse reactions and promotes a safer healthcare experience. For patients undergoing major surgeries, PBM offers the assurance of a carefully managed blood strategy that prioritizes their health, reduces the need for transfusions, and leads to quicker recovery times and shorter hospital stays.

For healthcare providers, PBM supports efficient and sustainable resource management by reducing reliance on donor blood, which is often in limited supply. With blood donation rates unable to keep pace with increasing demand, PBM helps preserve blood resources for patients with critical needs, such as trauma or severe bleeding cases. By reducing blood usage through optimized care and non-transfusion interventions, healthcare providers can manage resources more effectively, lowering the risk of blood shortages and ensuring that blood products are available when truly necessary. PBM also decreases costs associated with blood transfusions, including storage, screening, and administration expenses. This cost-efficiency is especially valuable in large hospitals and health systems, where managing blood resources effectively can lead to substantial financial savings.

Enhanced patient outcomes and quality of care are additional benefits of PBM, as it fosters a more patient-centered, individualized approach to healthcare. Through early anemia detection, blood-sparing surgical practices, and non-transfusion options, PBM enables healthcare providers to create personalized care plans tailored to each patient’s needs. This customized approach reduces the likelihood of complications and supports faster recoveries, improving patient satisfaction and overall quality of care. By proactively managing patients’ blood health, PBM minimizes hospital stays and readmissions, leading to a more streamlined healthcare experience. Together, these benefits improve both the clinical and operational aspects of healthcare delivery, supporting the goal of high-quality, cost-effective, and patient-centered care.

What Is Fueling the Growth in the Patient Blood Management Market?

The growth in the Patient Blood Management market is driven by the rising awareness of transfusion-related risks, increasing surgical and chronic disease cases, advancements in diagnostic and therapeutic technologies, and supportive regulatory policies promoting PBM adoption. As awareness grows around the risks and complications associated with blood transfusions, healthcare providers are increasingly seeking safer and more effective alternatives to traditional transfusion practices. Concerns over infections, immunologic reactions, and potential complications have highlighted the need for PBM programs that minimize transfusions and provide safer care options. This shift in clinical perspective has encouraged more hospitals and healthcare facilities to adopt PBM protocols, driving demand for technologies and practices that support comprehensive blood management.

Increasing numbers of surgeries and the rising prevalence of chronic diseases, such as cancer, kidney disease, and cardiovascular conditions, are also fueling the demand for PBM solutions. With these conditions often requiring surgical interventions or frequent hospitalizations, healthcare providers need effective blood management strategies to support patient care while reducing transfusion dependency. PBM protocols are particularly valuable in high-blood-loss surgeries, as they optimize patient blood health before and during procedures, decreasing the need for transfusions. As the volume of surgeries and hospitalizations continues to grow, so does the demand for effective PBM solutions to manage blood efficiently and improve patient outcomes.

Advancements in diagnostic and therapeutic technologies are significantly contributing to PBM market growth, as they enable more precise, effective, and personalized blood management strategies. New diagnostic tools, such as point-of-care testing and advanced anemia screening, allow for early intervention and accurate management of patient blood levels. Surgical innovations, including cell salvage devices and minimally invasive techniques, reduce blood loss during procedures, minimizing the need for donor blood. Pharmaceutical advancements, such as erythropoiesis-stimulating agents and intravenous iron supplements, provide non-transfusion treatment options for patients with anemia. These technological innovations make PBM programs more accessible and effective, supporting their adoption in hospitals and healthcare facilities worldwide.

Supportive regulatory policies and guidelines are also driving growth in the PBM market, as healthcare organizations and governments recognize the value of PBM in improving patient safety and optimizing blood resources. Regulatory bodies like the World Health Organization (WHO) and health ministries in several countries are encouraging healthcare providers to adopt PBM practices as part of their standard care protocols. Many healthcare systems now require hospitals to implement PBM strategies to comply with quality standards, reduce healthcare costs, and conserve blood resources. Additionally, patient advocacy groups and health organizations have increased educational efforts to promote awareness of PBM benefits among healthcare professionals and the public. These regulatory and advocacy efforts are expanding the adoption of PBM, driving significant growth in the market as providers align with best practices and compliance standards.

Together, these factors—awareness of transfusion risks, increasing surgical and chronic disease prevalence, technological advancements, and supportive regulatory frameworks—are driving robust growth in the Patient Blood Management market. As healthcare systems aim to provide safer, more cost-effective, and resource-efficient care, PBM is becoming a cornerstone of modern, patient-centered healthcare delivery.

SCOPE OF STUDY:

The report analyzes the Patient Blood Management market in terms of US$ Million by the following Component; End-Use; Product, and Geographic Regions/Countries:

Segments:

Product (Instruments, Reagents & Kits, Software, Accessories); Component (Whole Blood & Red Blood Cells, Plasma); End-Use (Blood Banks, Hospitals)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Asahi Kasei Medical Co. Ltd.
• B. Braun Melsungen AG
• Biomerieux SA
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche LTD.
• Fresenius Se & Co. KGaA
• Grifols, S.A.
• Haemonetics Corporation
• Immucor, Inc.
• Kaneka Corporation
• Livanova PLC
• Macopharma
• Terumo Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Patient Blood Management - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Focus on Blood Conservation Drives Demand for Patient Blood Management (PBM) Solutions
  • Rising Incidence of Chronic Diseases Expands Addressable Market for PBM
  • Advancements in Blood Transfusion Technologies Propel Market Growth
  • Growing Use of Point-of-Care Hemoglobin Testing Drives PBM Solutions
  • Patient Blood Management Crucial for Enhancing Surgical Outcomes
  • Use of AI for Blood Utilization Optimization Sets the Stage for PBM Growth
  • Increasing Demand for Bloodless Surgery Expands PBM Applications
  • Innovations in Anemia Management Propel PBM Market Expansion
  • Focus on Reducing Blood Transfusion-Related Risks Drives PBM Adoption
  • Use of PBM in Oncology Care Expands Market Opportunities
  • Growing Adoption in Emergency and Trauma Care Expands PBM Applications
  • Use of PBM in Geriatric Care Strengthens Market Opportunities
  • Strategic Investments in Automated Blood Management Solutions Propel PBM Growth
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Patient Blood Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Patient Blood Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Patient Blood Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Reagents & Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Accessories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Accessories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Accessories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Whole Blood & Red Blood Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Whole Blood & Red Blood Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Whole Blood & Red Blood Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Plasma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Plasma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Plasma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 24: World 16-Year Perspective for Blood Banks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 27: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 28: World Patient Blood Management Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• JAPAN
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• CHINA
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: China 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: China 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: China 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• EUROPE
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Patient Blood Management by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Patient Blood Management by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Europe 16-Year Perspective for Patient Blood Management by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• FRANCE
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: France 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: France 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: France 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• GERMANY
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Germany 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Italy 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Italy 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: UK 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: UK 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Spain 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Spain 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Russia 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Russia 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Rest of Europe 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Rest of Europe 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Patient Blood Management by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Patient Blood Management by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Asia-Pacific 16-Year Perspective for Patient Blood Management by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Asia-Pacific 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Australia 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Australia 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• INDIA
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: India 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: India 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: India 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: South Korea 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: South Korea 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Patient Blood Management by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Patient Blood Management by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Latin America 16-Year Perspective for Patient Blood Management by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Latin America 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Argentina 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Argentina 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Brazil 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Brazil 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: Mexico 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: Mexico 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: Rest of Latin America 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: Rest of Latin America 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Patient Blood Management by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Patient Blood Management by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 238: Middle East 16-Year Perspective for Patient Blood Management by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 241: Middle East 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 250: Iran 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 253: Iran 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 259: Israel 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 262: Israel 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 268: Saudi Arabia 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 271: Saudi Arabia 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 277: UAE 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 280: UAE 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 286: Rest of Middle East 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 289: Rest of Middle East 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
• AFRICA
  • Patient Blood Management Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Patient Blood Management by Product - Instruments, Reagents & Kits, Software and Accessories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 295: Africa 16-Year Perspective for Patient Blood Management by Product - Percentage Breakdown of Value Sales for Instruments, Reagents & Kits, Software and Accessories for the Years 2014, 2024 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Patient Blood Management by Component - Whole Blood & Red Blood Cells and Plasma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 298: Africa 16-Year Perspective for Patient Blood Management by Component - Percentage Breakdown of Value Sales for Whole Blood & Red Blood Cells and Plasma for the Years 2014, 2024 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Patient Blood Management by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Patient Blood Management by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Patient Blood Management by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030

IV. COMPETITION